cancer treatment

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.

Amphista Therapeutics presents three programs at AACR 2026, including oral presentation on AMX-883 BRD9 degrader for AML treatment.

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.

Syndax Pharmaceuticals attracted $6.54M institutional investment as its approved cancer therapies generated $172.4M revenue, up 629% year-over-year, driving 80%+ stock surge.

Regeneron commits $150M through 2036 to Science Talent Search, awarding $1.8M to 40 finalists in STEM fields.

Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.

Junshi Biosciences wins NMPA approval for JS001sc, first domestic subcutaneous anti-PD-1 drug across 12 indications, delivering clinical parity with IV formulation.

Iovance shows 60.6% fiscal 2025 revenue growth for its personalized cancer therapy Amtagvi, but faces manufacturing complexity and profitability challenges ahead.

MAIA Biotechnology prices $30M public offering at $1.50/share to fund clinical trials. Offering closes March 4, 2026.

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.

MacroGenics to participate in four major healthcare investor conferences in March 2026, with management presenting on pipeline developments and business operations.

Autolus to present pipeline updates and 2025 financial results at two March 2026 healthcare conferences, discussing commercial progress and strategic priorities.

Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.

Sensei Biotherapeutics stock surged 230% after acquiring Faeth Therapeutics and securing $200M investment, expanding its oncology pipeline with PIKTOR therapy.

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.

Perspective Therapeutics will release 2025 financial results and clinical pipeline updates on March 16, highlighting progress in its cancer-targeting radiopharmaceutical programs.

12+ companies advance iPSC-derived NK cell therapies for cancer treatment. Century Therapeutics and Fate Therapeutics report promising clinical progress in this expanding immunotherapy field.